Literature DB >> 147938

Repression of glial RNA transcription during the development of 6-aminonic-otinamide (6-AN)-induced acute gliopathy.

H I Sarkander, E Knoll-Köhler, J Cervos-Navarro.   

Abstract

Administration of 6-aminonicotinamide (6-AN) to rats leads to an opposite effect on the rate at which [3H]UMP is incorporated in vitro into nuclear cerebral neuronal and glial RNA. The inhibition of glial RNA synthesis is temporarily accompanied by both a reduction of the number of RNA initiation sites on glial chromatin and a reduction of [3H]acetate uptake into glial chromatin-bound histones mainly as regards the fraction H2B, H3 and H4. The slight stimulation of neuronal RNA synthesis 6 hours after 6-AN seemed to be caused exclusively by a less steric restriction of neuronal chromatin, whereas the more pronounced stimulation at 24 hours may be related to both a higher activity and/or amount of endogenous neuronal RNA polymerases and an increase in the total number of RNA initiation sites present on the neuronal chromatin. The increase in the total number of neuronal RNA initiation sites is closely parallel with a higher degree of acetylation of neuronal chromatin-bound histone fractions. The 6-AN-induced variations of glial and neuronal in vitro RNA synthesis are discussed in correlation with the neurotoxic action of 6-AN in vivo.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 147938

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  2 in total

1.  Correlated changes in neuronal cerebral rat brain RNA synthesis and hypo- and hypermotoric disorders induced by 6-aminonicotinamide (6-AN).

Authors:  E Knoll-Köhler; F Wojnorowicz; H J Sarkander
Journal:  Exp Brain Res       Date:  1980-01       Impact factor: 1.972

2.  Characteristics of transcriptionally active and inactive neuronal and nonastrocytic glial rat brain chromatin fractions.

Authors:  H I Sarkander; H J Dulce
Journal:  Exp Brain Res       Date:  1979-03-09       Impact factor: 1.972

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.